Bicara Therapeutics

Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class dual action biologics combining the precision of tumor-targeting antibodies with the power of tumor microenvironment modulators. Bicara’s lead program, BCA101, is a first-in-class bifunctional EGFR/TGF-β inhibitor in clinical development for multiple tumor ty

Pharmaceutical